Hologic (NASDAQ:HOLX) Issues Q2 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) updated its second quarter 2025 earnings guidance on Wednesday. The company provided EPS guidance of 1.000-1.030 for the period, compared to the consensus EPS estimate of 1.040. The company issued revenue guidance of $995.0 million-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on HOLX shares. Royal Bank of Canada lifted their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Raymond James increased their target price on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a report on Monday. Finally, BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Eight research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded up $1.22 during trading on Wednesday, hitting $72.80. 2,779,067 shares of the company traded hands, compared to its average volume of 2,293,025. The stock has a market capitalization of $16.43 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 2.35 and a beta of 0.98. Hologic has a one year low of $68.61 and a one year high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The business’s fifty day moving average is $72.91 and its 200-day moving average is $77.95.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. As a group, equities analysts predict that Hologic will post 4.28 earnings per share for the current fiscal year.

Insider Activity

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.